Cargando…
Inflammatory profile of convalescent plasma to treat COVID: Impact of amotosalen/UVA pathogen reduction technology
Blood products in therapeutic transfusion are now commonly acknowledged to contain biologically active constituents during the processes of preparation. In the midst of a worldwide COVID-19 pandemic, preliminary evidence suggests that convalescent plasma may lessen the severity of COVID-19 if admini...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585295/ https://www.ncbi.nlm.nih.gov/pubmed/36275757 http://dx.doi.org/10.3389/fimmu.2022.1034379 |
_version_ | 1784813461483552768 |
---|---|
author | Cognasse, Fabrice Hamzeh-Cognasse, Hind Duchez, Anne-Claire Shurko, Natalia Eyraud, Marie-Ange Arthaud, Charles-Antoine Prier, Amélie Heestermans, Marco Hequet, Olivier Bonneaudeau, Brigitte Rochette-Eribon, Sandrine Teyssier, Françoise Barlet-Excoffier, Valérie Chavarin, Patricia Legrand, Dominique Richard, Pascale Morel, Pascal Mooney, Nuala Tiberghien, Pierre |
author_facet | Cognasse, Fabrice Hamzeh-Cognasse, Hind Duchez, Anne-Claire Shurko, Natalia Eyraud, Marie-Ange Arthaud, Charles-Antoine Prier, Amélie Heestermans, Marco Hequet, Olivier Bonneaudeau, Brigitte Rochette-Eribon, Sandrine Teyssier, Françoise Barlet-Excoffier, Valérie Chavarin, Patricia Legrand, Dominique Richard, Pascale Morel, Pascal Mooney, Nuala Tiberghien, Pierre |
author_sort | Cognasse, Fabrice |
collection | PubMed |
description | Blood products in therapeutic transfusion are now commonly acknowledged to contain biologically active constituents during the processes of preparation. In the midst of a worldwide COVID-19 pandemic, preliminary evidence suggests that convalescent plasma may lessen the severity of COVID-19 if administered early in the disease, particularly in patients with profound B-cell lymphopenia and prolonged COVID-19 symptoms. This study examined the influence of photochemical Pathogen Reduction Treatment (PRT) using amotosalen‐HCl and UVA light in comparison with untreated control convalescent plasma (n= 72 – paired samples) - cFFP, regarding soluble inflammatory factors: sCD40L, IFN-alpha, IFN-beta, IFN-gamma, IL-1 beta, IL-6, IL-8, IL-10, IL-18, TNF-alpha and ex-vivo inflammatory bioactivity on endothelial cells. We didn’t observe significant modulation of the majority of inflammatory soluble factors (8 of 10 molecules tested) pre- or post-PRT. We noted that IL-8 concentrations were significantly decreased in cFFP with PRT, whereas the IL-18 concentration was increased by PRT. In contrast, endothelial cell release of IL-6 was similar whether cFFP was pre-treated with or without PRT. Expression of CD54 and CD31 in the presence of cFFP were similar to control levels, and both were significant decreased in when cFFP had been pre-treated by PRT. It will be interesting to continue investigations of IL-18 and IL-8, and the physiopathological effect of PRT- treated convalescent plasma and in clinical trials. But overall, it appears that cFFP post-PRT were not excessively pro-inflammatory. Further research, including a careful clinical evaluation of CCP-treated patients, will be required to thoroughly define the clinical relevance of these findings. |
format | Online Article Text |
id | pubmed-9585295 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95852952022-10-22 Inflammatory profile of convalescent plasma to treat COVID: Impact of amotosalen/UVA pathogen reduction technology Cognasse, Fabrice Hamzeh-Cognasse, Hind Duchez, Anne-Claire Shurko, Natalia Eyraud, Marie-Ange Arthaud, Charles-Antoine Prier, Amélie Heestermans, Marco Hequet, Olivier Bonneaudeau, Brigitte Rochette-Eribon, Sandrine Teyssier, Françoise Barlet-Excoffier, Valérie Chavarin, Patricia Legrand, Dominique Richard, Pascale Morel, Pascal Mooney, Nuala Tiberghien, Pierre Front Immunol Immunology Blood products in therapeutic transfusion are now commonly acknowledged to contain biologically active constituents during the processes of preparation. In the midst of a worldwide COVID-19 pandemic, preliminary evidence suggests that convalescent plasma may lessen the severity of COVID-19 if administered early in the disease, particularly in patients with profound B-cell lymphopenia and prolonged COVID-19 symptoms. This study examined the influence of photochemical Pathogen Reduction Treatment (PRT) using amotosalen‐HCl and UVA light in comparison with untreated control convalescent plasma (n= 72 – paired samples) - cFFP, regarding soluble inflammatory factors: sCD40L, IFN-alpha, IFN-beta, IFN-gamma, IL-1 beta, IL-6, IL-8, IL-10, IL-18, TNF-alpha and ex-vivo inflammatory bioactivity on endothelial cells. We didn’t observe significant modulation of the majority of inflammatory soluble factors (8 of 10 molecules tested) pre- or post-PRT. We noted that IL-8 concentrations were significantly decreased in cFFP with PRT, whereas the IL-18 concentration was increased by PRT. In contrast, endothelial cell release of IL-6 was similar whether cFFP was pre-treated with or without PRT. Expression of CD54 and CD31 in the presence of cFFP were similar to control levels, and both were significant decreased in when cFFP had been pre-treated by PRT. It will be interesting to continue investigations of IL-18 and IL-8, and the physiopathological effect of PRT- treated convalescent plasma and in clinical trials. But overall, it appears that cFFP post-PRT were not excessively pro-inflammatory. Further research, including a careful clinical evaluation of CCP-treated patients, will be required to thoroughly define the clinical relevance of these findings. Frontiers Media S.A. 2022-10-07 /pmc/articles/PMC9585295/ /pubmed/36275757 http://dx.doi.org/10.3389/fimmu.2022.1034379 Text en Copyright © 2022 Cognasse, Hamzeh-Cognasse, Duchez, Shurko, Eyraud, Arthaud, Prier, Heestermans, Hequet, Bonneaudeau, Rochette-Eribon, Teyssier, Barlet-Excoffier, Chavarin, Legrand, Richard, Morel, Mooney and Tiberghien https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Cognasse, Fabrice Hamzeh-Cognasse, Hind Duchez, Anne-Claire Shurko, Natalia Eyraud, Marie-Ange Arthaud, Charles-Antoine Prier, Amélie Heestermans, Marco Hequet, Olivier Bonneaudeau, Brigitte Rochette-Eribon, Sandrine Teyssier, Françoise Barlet-Excoffier, Valérie Chavarin, Patricia Legrand, Dominique Richard, Pascale Morel, Pascal Mooney, Nuala Tiberghien, Pierre Inflammatory profile of convalescent plasma to treat COVID: Impact of amotosalen/UVA pathogen reduction technology |
title | Inflammatory profile of convalescent plasma to treat COVID: Impact of amotosalen/UVA pathogen reduction technology |
title_full | Inflammatory profile of convalescent plasma to treat COVID: Impact of amotosalen/UVA pathogen reduction technology |
title_fullStr | Inflammatory profile of convalescent plasma to treat COVID: Impact of amotosalen/UVA pathogen reduction technology |
title_full_unstemmed | Inflammatory profile of convalescent plasma to treat COVID: Impact of amotosalen/UVA pathogen reduction technology |
title_short | Inflammatory profile of convalescent plasma to treat COVID: Impact of amotosalen/UVA pathogen reduction technology |
title_sort | inflammatory profile of convalescent plasma to treat covid: impact of amotosalen/uva pathogen reduction technology |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585295/ https://www.ncbi.nlm.nih.gov/pubmed/36275757 http://dx.doi.org/10.3389/fimmu.2022.1034379 |
work_keys_str_mv | AT cognassefabrice inflammatoryprofileofconvalescentplasmatotreatcovidimpactofamotosalenuvapathogenreductiontechnology AT hamzehcognassehind inflammatoryprofileofconvalescentplasmatotreatcovidimpactofamotosalenuvapathogenreductiontechnology AT duchezanneclaire inflammatoryprofileofconvalescentplasmatotreatcovidimpactofamotosalenuvapathogenreductiontechnology AT shurkonatalia inflammatoryprofileofconvalescentplasmatotreatcovidimpactofamotosalenuvapathogenreductiontechnology AT eyraudmarieange inflammatoryprofileofconvalescentplasmatotreatcovidimpactofamotosalenuvapathogenreductiontechnology AT arthaudcharlesantoine inflammatoryprofileofconvalescentplasmatotreatcovidimpactofamotosalenuvapathogenreductiontechnology AT prieramelie inflammatoryprofileofconvalescentplasmatotreatcovidimpactofamotosalenuvapathogenreductiontechnology AT heestermansmarco inflammatoryprofileofconvalescentplasmatotreatcovidimpactofamotosalenuvapathogenreductiontechnology AT hequetolivier inflammatoryprofileofconvalescentplasmatotreatcovidimpactofamotosalenuvapathogenreductiontechnology AT bonneaudeaubrigitte inflammatoryprofileofconvalescentplasmatotreatcovidimpactofamotosalenuvapathogenreductiontechnology AT rochetteeribonsandrine inflammatoryprofileofconvalescentplasmatotreatcovidimpactofamotosalenuvapathogenreductiontechnology AT teyssierfrancoise inflammatoryprofileofconvalescentplasmatotreatcovidimpactofamotosalenuvapathogenreductiontechnology AT barletexcoffiervalerie inflammatoryprofileofconvalescentplasmatotreatcovidimpactofamotosalenuvapathogenreductiontechnology AT chavarinpatricia inflammatoryprofileofconvalescentplasmatotreatcovidimpactofamotosalenuvapathogenreductiontechnology AT legranddominique inflammatoryprofileofconvalescentplasmatotreatcovidimpactofamotosalenuvapathogenreductiontechnology AT richardpascale inflammatoryprofileofconvalescentplasmatotreatcovidimpactofamotosalenuvapathogenreductiontechnology AT morelpascal inflammatoryprofileofconvalescentplasmatotreatcovidimpactofamotosalenuvapathogenreductiontechnology AT mooneynuala inflammatoryprofileofconvalescentplasmatotreatcovidimpactofamotosalenuvapathogenreductiontechnology AT tiberghienpierre inflammatoryprofileofconvalescentplasmatotreatcovidimpactofamotosalenuvapathogenreductiontechnology |